All Drug Development articles – Page 30
-
ArticleTherapeutic frontiers: the potential of RRx-001 and AdAPT-001
Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.
-
ArticleHuntington's disease and potential therapies
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.
-
NewsCracking the code of influenza evolution
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
-
ArticlePrecision medicine: exploring the impact of DNA Testing
The potential of precision medicine requires a small shift in perspective, Patrick Short, CEO and co-founder of Sano Genetics, explains in this Q&A.
-
ReportBeyond the lab: cell & gene therapy
The launch of our new series, "Beyond the Lab," promises to deliver high-level insights commissioned exclusively by Drug Target Review magazine. Our inaugural report is an exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery.
-
ArticleGenetic variant identification: unveiling the power of STING-seq
In an exclusive interview, Dr Neville Sanjana, Associate Professor of biology at NYU and a core faculty member at the New York Genome Center, discusses the breakthrough study on STING-seq.
-
WebinarFunctional assays for the development of agonistic antibodies
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
-
ArticleNavigating the challenges and opportunities of AI in drug development and personalised medicine
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
-
ArticleBiochemical assays and deep cyclic inhibition in cancer treatment
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief Scientific Officer at Immuneering, about his company’s aim to develop a universal-RAS therapy.
-
ArticleThe future of central nervous system research
Central nervous system (CNS) research is making breakthroughs with innovative therapies and next-generation technologies. Researchers are now able to use human tissue to identify relevant novel drug targets and biomarkers for a broad range of CNS diseases including schizophrenia, Alzheimer’s disease and Parkinson’s disease. As our understanding of the brain ...
-
ArticleRare autoantibody diseases: an innovative targeted pathway
Dr Katie Abouzahr outlines how precision targeting utilising the neonatal fragment crystallisable receptor pathway may provide accessible new treatments for autoantibody diseases.
-
ArticleEpigenetic editing: the next generation of genetic medicine
Dr Blythe Sather at Tune Therapeutics reveals why epigenetic editing offers benefits above and beyond those of gene editing, potentially bridging the gaps to breakthroughs in the clinic.
-
ArticleExploring alternatives to animal testing in drug discovery
The use of animal studies in drug development has become a growing ethical concern, particularly given the high failure rate of clinical trials, which can reach up to 90 percent. This article highlights non-animal models that could expedite the drug delivery process from bench to bedside.
-
ArticleTargeted protein degradation: turning undruggable targets into druggable targets
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation, ...
-
ArticleThe promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
-
ArticleA 3D tool for measuring intracellular lipid droplets
Tomographic phase microscopy in flow cytometry showcases its ability to accurately measure intracellular lipid droplets.
-
ArticleNext-generation CAR T cells
Dr John Maher discusses the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours.
-
ArticleWomen in STEM with Dr Jo Brewer
Come and join us for our monthly series highlighting Women in STEM. We are excited to present the latest edition for June, featuring an exclusive interview with Dr Jo Brewer, Chief Scientific Officer at Adaptimmune. With a remarkable 15-years of experience in cell therapy, Jo's passion for cells has been ...
-
ArticleDrug Target Review Screening eBook 2023
In this eBook, uncover the transformative potential of AI/ML in single-cell technologies and gain insights into disease progression.
-
NewsNew detection system for viral infections helps vaccine and drug development
Out of the US, a newly developed a rapid, stain-free, and automated viral plaque detection system enabled by holography and deep learning, is a cost-effective way of observing the formation of viral plaques caused by viral infections over a layer of cells.